Welcome to PHARMAECONOMICA
Your Trusted Partner in Life Science Consulting
PHARMAECONOMICA provides independent consulting services tailored specifically to the needs of the life science industry. With our expertise and deep industry knowledge, we understand the unique challenges and opportunities that pharmaceutical, biotechnology, and medical device companies face in today's dynamic landscape.
Our team of industry experts combines scientific expertise, market insights, and commercial acumen to provide you with a holistic approach to success. We go beyond traditional consulting services to deliver tailored strategies and actionable recommendations that propel your business forward.
With our in-depth analysis and keen understanding of the life science ecosystem, we help you identify and address the key factors that impact success rates. Whether it's AI-driven drug discovery, optimizing clinical trial design, or developing robust commercialization strategies, we have you covered at every step of the way.
By partnering with PHARMAECONOMICA, you gain a competitive edge in the market. Our proprietary platforms, proven methodologies, data-driven insights, and extensive industry network empower you to make informed decisions and seize opportunities that lead to sustainable growth and profitability.
We are committed to improving people' lives
Alzheimer's is a type of dementia that affects memory, thinking, and behavior. Worldwide, at least 55 million people are believed to be living with Alzheimer's disease or other dementias. The role of Butyrylcholinesterase (BuChE) in Alzheimer's disease has been extensively studied, and it is believed to play a significant role in the progression of the disease. Targeting BuChE with inhibitors has emerged as a potential therapeutic strategy to alleviate the symptoms and slow down the cognitive decline associated with Alzheimer's, making it a critical focus in drug discovery efforts for this devastating condition.
Our cutting-edge AI-driven Drug discovery technology has successfully identified two highly potent Butyrylcholinesterase (BuChE) inhibitors with IC50 values ranging from 0.9 to 2.5 µM as validated through several enzyme-based assays. Furthermore, Parallel Artificial Membrane Permeability Assays (PAMPA) have been conducted to examine these compounds' membrane permeability, another essential parameter in predicting their potential as oral drugs, and both lead compounds exhibited profound permeability, compared to the control, corticosterone.
PE01: PE01 demonstrated substantial inhibition of equine BuChE, showing 98% inhibition. The IC50 value, which is the concentration of the compound where 50% of the enzyme is inhibited, was found to be 903 nM (0.9 µM) (average of two trials). This value is promising and suggests that PE01 is a potent inhibitor of BuChE.
PE02: PE02 also showed good inhibition of BuChE at 94%. However, its IC50 value was higher than PE02, averaging 2515 nM (2.5 µM). This indicates that while PE02 is an effective BuChE inhibitor, it requires a higher concentration compared to PE01 to achieve comparable inhibition.
Currently, we are performing an in-depth in silico study of these lead compounds. This study includes molecular docking, Molecular Dynamics (MD) simulations, and in silico ADME prediction to understand the structural aspects contributing to the potency of these compounds. The compounds identified and optimized through the in-silico studies will be subjected to experimental validation.
The identification of these lead compounds highlights the immense potential of our Insilico Drug Discovery Platform in accelerating the identification and optimization of novel drug candidates. By seamlessly integrating computational methods with experimental validation, we enable researchers and pharmaceutical companies to save valuable time and resources in the drug discovery process.
We unlock the power of data-driven decision making with our tailored mathematical and statistical models. Our cutting-edge in-house platforms provide a risk-free environment for evaluating optimal solutions and serve as a basis for mathematical optimization. With advanced algorithms and techniques, we transform complex data into actionable insights, empowering you to make informed decisions with confidence. Our customized models are designed to meet your unique needs, ensuring accuracy and effectiveness. Experience the difference of data-driven decision making and gain a competitive edge in the ever-evolving business landscape.
Insilico Drug Discovery
We excel in the pivotal stages of hit identification and hit-to-lead optimization. This is where science meets innovation, as we harness the potential of promising molecular structures and transform them into exceptional drug candidates.
We utilize cutting-edge physics-based simulations and machine learning to revolutionize drug discovery across various therapeutic fields. Our services expedite the process of finding potential drug candidates, leading to more efficient and effective drug development. Partner with us to unlock new possibilities in advancing healthcare through innovative pharmaceutical solutions.
Value-Based Drug Development
We are dedicated to transforming the drug development landscape with our value-based approach. Our comprehensive services optimize every aspect of the process, from discovery to commercialization, to deliver therapies that truly make a difference.
By leveraging real-world evidence, advanced analytics, and innovative pricing strategies, we ensure that your drug candidates align with payer requirements, increasing market access and maximizing reimbursement potential. With a focus on patient outcomes and cost-effectiveness, we secure maximizing your return on investment.
Health Economics and Outcome Research (HEOR)
Health economics and outcome research play a critical role in today's healthcare landscape.
Our dedicated team of HEOR specialists conducts comprehensive assessments to evaluate the cost-effectiveness, budget impact, and patient outcomes of your healthcare interventions. We follow industry best practices and adhere to international guidelines to ensure the reliability, validity, and integrity of our analyses. We equip your organization with the insights needed to demonstrate the value of your products to stakeholders and to optimize market access.
"I would like to share that it was a pleasure to have Jorge on my team as he brought knowledge to a growing Market Access team within his area of expertise. He is trustworthy, a true team player and enjoys collaboration with other departments and with our affiliates. He developed a strong relationship with our external vendors, and this created a very reliable working model for Jorge to deliver his projects on time. He is detailed oriented, hard worker and professional . He enjoys sharing information and always focuses on making sure that he informs and updates his team members accordingly. Jorge has the ability to work in any matrix and his personality allows for an easy acceptance by his peers. Jorge is an expert in his area and will bring a lot of value to any organization he works in."